Navigation Links
Intellect Neurosciences Responds to Official Action by United States Patent and Trademark Office in Relation to its ANTISENILIN® Alzheimer's Patent Application
Date:11/3/2011

NEW YORK, Nov. 3, 2011 /PRNewswire/ -- Intellect Neurosciences, Inc. (OTCBB: ILNS), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it has filed a response and request for continued examination (RCE) in its antibody methods application Serial  No. 10/084,380, one of several applications pending in the United States in relation to the Company's ANTISENILIN® platform technology.   Corresponding patents have been issued in Europe, Japan, China and several other countries. The response is accompanied by a written declaration of support from an internationally recognized US-based expert in the field of therapeutic antibodies.  

"We are gratified once again by the support of this internationally recognized expert who previously was instrumental in persuading the patent examiner to withdraw different grounds for rejection of the same patent application," commented Daniel G. Chain, Ph.D., Chairman and CEO of Intellect Neurosciences.  "We are optimistic that the expert explanation will help to address and overcome the Patent Office position on our pending patent application and lead to an allowance of our method of treatment claims."

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. develops innovative approaches aimed at arresting or preventing Alzheimer's disease, and other neurodegenerative diseases especially focused on proteinopathies. Intellect's pipeline includes small neuroprotective molecules and neoepitope-based immunotherapy approaches including monoclonal antibodies and vaccines targeting beta amyloid and abnormal tau proteins. The company is currently developing three separate platform technologies:  ANTISENILIN® is Intellect's Alzheimer's beta amyloid monoclonal antibody platform technology which underlies several products in advanced
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Intellect Neurosciences Announces Its New CONJUMAB-A Platform Technology for Novel Treatments of Alzheimers Disease and Other Proteinopathies
2. Intellect Neurosciences Issues Letter to Shareholders
3. Intellect Neurosciences CEO to be Featured on Wall Street Reporter
4. ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreichs Ataxia
5. IRIDEX Licenses the Exclusive Rights to Ophthalmology Products and Intellectual Property from Ocunetics, Inc.
6. PILMA Vows to Redouble Support for Increased Protections Against Intellectual Property Theft
7. Dehaier Strengthens Intellectual Property Portfolio
8. NMT Medical, Inc. Adds Intellectual Property to Its Sealed Bid Sale of Friday, June 10, 2011 at Twelve OClock Noon
9. GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling
10. Inovio Pharmaceuticals Market-Leading Intellectual Property Recognized by MDB Capital Award
11. NMT Medical, Inc. Sealed Bid Sale of its Intellectual Property to Take Place Friday, June 10, 2011 at Twelve OClock Noon
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  AMETEK, Inc. (NYSE: ... Kurtis L. Goos as Vice President and ... Interconnects and Packaging (EMIP) Division. "I am ... general management and business development experience, especially in the ... important contributions to the continued growth and success of ...
(Date:7/25/2014)... , July 25, 2014 Leading ... is returning for the seventh year to São Paulo, ... 7 th August 2014. The event will co-locate with ... most comprehensive meeting point for the pharmaceutical industry. ... top 25 countries for pharmaceutical sales are now exploring the ...
(Date:7/25/2014)... July 25, 2014  Arena Pharmaceuticals, Inc. (NASDAQ: ... corporate update and report second quarter 2014 financial results ... August 1, 2014. That same day, Arena will host ... Time (5:30 a.m. Pacific Time). The ... domestic callers and 914.495.8552 for international callers. Please specify ...
Breaking Medicine Technology:AMETEK Names Kurtis L. Goos, Vice President & General Manager, Engineered Medical Components 2CPhI South America 2014 Launches with Generics Showing Huge Growth 2CPhI South America 2014 Launches with Generics Showing Huge Growth 3CPhI South America 2014 Launches with Generics Showing Huge Growth 4Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 2Arena Pharmaceuticals to Host Corporate Update and Financial Results Conference Call and Webcast on Friday, August 1 3
... WIRE)--Apr 3, 2007 - Allon,Therapeutics Inc. ... the publication of new preclinical data ... Allon's product,candidate AL-108 significantly reduces the ... of tau protein in the brain,two ...
... 03, 2007 /PRNewswire/ -- Southern,Research Institute, a not-for-profit ... areas of preclinical drug,discovery and drug development today ... presentation and 10 poster,presentations at the 2007 American ... in Los Angeles, Calif. , Anshu Mittal Roy ...
Cached Medicine Technology:Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 2Allon Therapeutics to Present New Data at Leerink Swann Alzheimer's,Conference 3Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 2Southern Research Institute to Present at the 2007 American,Association For Cancer Research Annual Meeting 3
(Date:7/25/2014)... NC (PRWEB) July 25, 2014 Researchers at ... the results of a study indicating that a man-made material ... mesothelioma among workers exposed to asbestos. Surviving Mesothelioma has just ... to read it now. , The French scientists ... developed mesothelioma between 1987 and 2006. One group of ...
(Date:7/25/2014)... 25, 2014 Healthpointe is proud ... clinic is offering Occupational Medicine services to the ... accepting referrals and workers’ compensation cases. , ... clinic include wound care treatment management, return-to-work and ... pre-employment screening & physicals, and illness and injury ...
(Date:7/25/2014)... the leading pan-European association representing medical oncology professionals, ... Data Protection Regulation [1] could make cancer research ... doctors and cancer patients. , The proposed wording ... patient consent, meaning that researchers would have to ... in order to consult their data or use ...
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The House of Yahweh ... revealing to the whole world, including even the most devout ... in his new article. , Yisrayl says it all started ... by the Catholic Church. He says this plan included removing ... and replacing it with titles such as Lord and God. ...
(Date:7/25/2014)... According to the Addict Him To You Pdf ... guide that teaches women how to get the love of ... its review that this book consists of 4 parts, including:, ... won’t commit yet (and what to do about it) , ... ,     Part 3: How to touch his heart ...
Breaking Medicine News(10 mins):Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 2Health News:New Study Shows Mesothelioma Risk is Higher in Workers Exposed to Man-Made Insulator, According to Surviving Mesothelioma 3Health News:Healthpointe Offering Occupational Medicine Services in La Mirada 2Health News:Is Europe putting cancer research at risk? 2Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3
... -- A program that helps elementary school students develop ... science and cultural studies may be one way to ... United States. In a new study, researchers assessed ... in which students explore, prepare and enjoy fresh, affordable ...
... 2011 A two-year study of patients in the ... (TAVR) in patients who have severe aortic stenosis and ... one-year findings and support the role of TAVR as ... today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) ...
... NOVEMBER 10, 2011 Results of the PARTNER ... replacement (TAVR) results in improved quality of life compared ... the transfemoral approach. The results of the study were ... (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation. ...
... thinking about Parkinson,s disease is that it,s a disorder of ... brain,s substantia nigra to die or become impaired. A study ... a hereditary form of Parkinson,s disease cause mitochondria to run ... to stop them. Findings appear in the November 11 issue ...
... physicians for increasing the volume of visits and procedures ... health outcomes," the American College of Physicians (ACP) today ... Pensions (HELP) in a hearing on Improving Quality, Lowering ... does not provide incentives for physicians to coordinate care; ...
... News) -- All the color variations seen in prehistoric ... populations, which indicates that the ancient human artists accurately ... The research is also the first to provide ... Previous DNA studies produced evidence only for bay (reddish ...
Cached Medicine News:Health News:Cooking Class Benefits Kids in Many Ways 2Health News:Results of the PARTNER Trial Cohort B 2-year follow up presented at TCT 2011 2Health News:Quality of life benefits of transcatheter aortic valve replacement differ by access site 2Health News:Why do neurons die in Parkinson's disease? 2Health News:Internists express strong support for ACA's programs to support coordinated care 2Health News:Cave Art Accurately Depicted Horses of Different Colors 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: